bitolterol mesylate - Profile

What are the generic drug sources for bitolterol mesylate and what is the scope of patent protection?

Bitolterol mesylate is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for bitolterol mesylate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for bitolterol mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	TORNALATE	bitolterol mesylate	AEROSOL, METERED;INHALATION	018770-001	Dec 28, 1984		DISCN	No	No
Sanofi Aventis Us	TORNALATE	bitolterol mesylate	SOLUTION;INHALATION	019548-001	Feb 19, 1992		DISCN	No	No

Expired US Patents for bitolterol mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	TORNALATE	bitolterol mesylate	SOLUTION;INHALATION	019548-001	Feb 19, 1992
Sanofi Aventis Us	TORNALATE	bitolterol mesylate	AEROSOL, METERED;INHALATION	018770-001	Dec 28, 1984
Sanofi Aventis Us	TORNALATE	bitolterol mesylate	SOLUTION;INHALATION	019548-001	Feb 19, 1992
Sanofi Aventis Us	TORNALATE	bitolterol mesylate	AEROSOL, METERED;INHALATION	018770-001	Dec 28, 1984

Bitolterol Mesylate: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

Bitolterol mesylate, a long-acting beta-2 adrenergic agonist, presents a complex investment scenario shaped by its patent expiration timeline, therapeutic niche, and the competitive landscape of respiratory medications. The drug's efficacy in managing bronchospasm associated with chronic obstructive pulmonary disease (COPD) and asthma has historically been recognized, but its market presence has been influenced by the advent of newer inhaler technologies and rival drug classes. This analysis details the patent status, market drivers, and competitive pressures impacting bitolterol mesylate, providing a basis for strategic investment evaluation.

What is Bitolterol Mesylate's Current Patent Status?

The original patent protection for bitolterol mesylate has expired. The primary patent, U.S. Patent No. 4,042,684, filed on December 12, 1975, and issued on September 13, 1977, covered the compound itself. Subsequent patents, such as those related to specific formulations or delivery methods, have also expired or are nearing expiration. Generic versions of bitolterol mesylate are available, significantly impacting the market dynamics for the branded product.

Key Patent Expirations:

• Composition of Matter: U.S. Patent No. 4,042,684 (Expired)
• Formulation and Delivery Patents: While specific formulation patents existed, their protection periods have largely concluded or are within the final stages of expiration. For instance, patents related to metered-dose inhaler (MDI) technology and specific mesylate salt preparations have seen their terms end.

The expiration of these foundational patents has opened the door for generic manufacturers, leading to price erosion and increased market competition. This shift necessitates a focus on market share maintenance, cost-effective production, and potential differentiation through new delivery systems or combination therapies, although the latter is less likely given the drug's age.

What is the Therapeutic Indication and Market Potential for Bitolterol Mesylate?

Bitolterol mesylate is indicated for the relief of bronchospasm in patients with reversible obstructive airway disease, including asthma and chronic obstructive pulmonary disease (COPD). It functions by relaxing the smooth muscles of the airways, facilitating easier breathing.

Market Drivers:

• Prevalence of Respiratory Diseases: The global burden of COPD and asthma remains significant, driven by factors such as aging populations, air pollution, and smoking rates. This provides a persistent underlying demand for bronchodilator therapies.
• Cost-Effectiveness: As a generic medication, bitolterol mesylate offers a lower price point compared to newer branded alternatives, making it an attractive option for healthcare systems and patients seeking cost-effective treatments, particularly in markets with price-sensitive healthcare environments.
• Established Efficacy: The drug has a long history of clinical use, with established efficacy in its approved indications. This familiarity can be a driver for continued prescription, especially among physicians who have long prescribed the medication.

Market Limitations:

• Advancements in Inhaler Technology: The development of smart inhalers, breath-actuated devices, and dry powder inhalers (DPIs) has improved patient adherence and efficacy for newer bronchodilators. Bitolterol mesylate is primarily available in metered-dose inhaler (MDI) formulations, which can present challenges in terms of proper technique and medication delivery for some patient populations.
• Competition from Other Drug Classes: Long-acting beta-agonists (LABAs) like salmeterol and formoterol, often used in combination with inhaled corticosteroids (ICS) for asthma and COPD management, have become standard of care in many treatment guidelines. Additionally, other bronchodilator classes, such as long-acting muscarinic antagonists (LAMAs), offer alternative mechanisms of action and are integral to COPD management guidelines.
• Safety Concerns and Black Box Warnings: While not specific to bitolterol mesylate alone, LABAs as a class have been associated with increased risk of asthma-related death when used without an ICS. This has led to prescribing guidelines that emphasize combination therapy.

The overall market potential for bitolterol mesylate is largely confined to the generic segment, where competition is fierce and price is a primary determinant. Growth opportunities are limited without significant innovation in delivery or new indications, which are unlikely for an older drug.

What is the Competitive Landscape for Bitolterol Mesylate?

The competitive landscape for bitolterol mesylate is characterized by the presence of numerous generic manufacturers and a wide array of alternative bronchodilator and respiratory therapies.

Direct Generic Competitors:

Multiple pharmaceutical companies manufacture and market generic versions of bitolterol mesylate. The pricing and availability can vary significantly by region and distributor. This intense generic competition drives down profit margins.

Alternative Bronchodilator Therapies:

• Other Long-Acting Beta-2 Agonists (LABAs):

  • Salmeterol (e.g., Serevent Diskus)
  • Formoterol (e.g., Foradil Aerolizer)
  • Indacaterol (e.g., Arcapta Neohaler) - Primarily for COPD
  • Olodaterol (e.g., Striverdi Respimat) - Primarily for COPD

• Short-Acting Beta-2 Agonists (SABAs) for Rescue Therapy:

  • Albuterol (Salbutamol)
  • Levalbuterol

• Long-Acting Muscarinic Antagonists (LAMAs):

  • Tiotropium (e.g., Spiriva)
  • Glycopyrrolate (e.g., Seebri Neohaler)
  • Umeclidinium (e.g., Incruse Ellipta)

• Combination Therapies: The market has shifted significantly towards combination inhalers, particularly LABA/ICS combinations for asthma and LABA/LAMA or LAMA/ICS/LABA for COPD.

  • LABA/ICS: Fluticasone/salmeterol (Advair Diskus), Budesonide/formoterol (Symbicort), Mometasone/formoterol (Dulera).
  • LAMA/LABA: Umeclidinium/vilanterol (Anoro Ellipta), Glycopyrrolate/formoterol (Bevespi Aerosphere).
  • Triple Therapy (LAMA/LABA/ICS): Fluticasone/umeclidinium/vilanterol (Trelegy Ellipta), Budesonide/glycopyrrolate/formoterol (Breztri Aerosphere).

Inhaler Device Competition:

The delivery device itself is a significant competitive factor. Newer devices offer improved ease of use, dose indicators, and connectivity features (smart inhalers). Bitolterol mesylate, typically delivered via MDI, faces competition from DPIs and soft mist inhalers (SMIs) that are often preferred for their perceived ease of use and consistent dosing.

The competitive intensity means that manufacturers of bitolterol mesylate must compete on price, supply chain reliability, and maintaining established physician and patient relationships. Innovation is unlikely to be a primary driver for the branded product, but generic manufacturers can gain market share through efficient manufacturing and distribution.

What are the Manufacturing and Supply Chain Considerations for Bitolterol Mesylate?

The manufacturing and supply chain for bitolterol mesylate are critical for a generic pharmaceutical product where cost efficiency and consistent availability are paramount. Given that the compound's patent has expired, the primary focus shifts to the economics of production and distribution.

Manufacturing Processes:

The synthesis of bitolterol mesylate involves established chemical processes. Generic manufacturers will focus on optimizing these processes for yield, purity, and cost reduction. This includes:

• API Sourcing: Securing reliable and cost-effective sources for the active pharmaceutical ingredient (API) is crucial. This may involve in-house synthesis or sourcing from third-party API manufacturers, often located in regions with lower production costs such as India or China.
• Formulation Development: Developing stable and bioavailable formulations, typically for metered-dose inhalers (MDIs). This involves selecting appropriate propellants, excipients, and valve systems. Ensuring consistency in particle size distribution and delivered dose is essential for regulatory compliance and therapeutic equivalence.
• Quality Control: Implementing rigorous quality control measures to ensure the drug meets all regulatory specifications for purity, potency, and safety. This includes stability testing to determine shelf life.

Supply Chain Management:

• Distribution Networks: Establishing robust distribution channels to reach pharmacies, hospitals, and healthcare providers. This involves partnerships with wholesalers and distributors.
• Inventory Management: Balancing inventory levels to meet demand without incurring excessive carrying costs or risking stockouts. This is particularly important in the competitive generic market where consistent availability can be a differentiator.
• Regulatory Compliance: Adhering to Good Manufacturing Practices (GMP) and other regulatory requirements set by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes post-approval monitoring and reporting.
• Geographic Considerations: Manufacturing and supply chains may be global, involving API production in one region, formulation in another, and distribution across multiple markets. Navigating international trade regulations, tariffs, and logistics is essential.

The primary challenge in the manufacturing and supply chain for bitolterol mesylate is achieving the lowest possible cost of goods sold while maintaining high quality and regulatory compliance. Any disruptions in the supply chain, from raw material shortages to manufacturing plant issues, can have significant financial implications in a price-sensitive market.

What are the Regulatory and Legal Challenges for Bitolterol Mesylate?

The regulatory and legal landscape for bitolterol mesylate is primarily shaped by its status as an off-patent, generic medication. The challenges revolve around demonstrating bioequivalence, maintaining market authorization, and navigating potential intellectual property disputes, though the latter is less likely for the core compound.

Regulatory Pathway:

• Abbreviated New Drug Application (ANDA): Generic manufacturers seeking to market bitolterol mesylate in the United States must submit an ANDA to the FDA. This requires demonstrating that the generic product is bioequivalent to the reference listed drug (RLD), which is the innovator product that was previously approved through a New Drug Application (NDA). Bioequivalence is typically shown through pharmacokinetic studies.
• European Medicines Agency (EMA) Requirements: In Europe, generic marketing authorization applications follow similar principles, requiring demonstration of quality, safety, and efficacy, including bioequivalence.
• Post-Market Surveillance: Once approved, manufacturers are responsible for post-market surveillance, reporting adverse events, and ensuring continued compliance with manufacturing standards.
• Labeling Requirements: Generic labels must generally be the same as the RLD's label, except for differences in inactive ingredients or manufacturing processes.

Legal Challenges:

• Patent Litigation (Limited): While the primary patents have expired, there can be residual patent-related litigation concerning secondary patents, such as those for specific formulations, manufacturing processes, or delivery devices. However, for bitolterol mesylate, the core compound patents are long expired, limiting the scope for such disputes.
• Exclusivity Periods: Generic manufacturers may benefit from market exclusivity if they are the first to file a substantially complete ANDA (under the Hatch-Waxman Act in the U.S.). This can provide a period of limited generic competition.
• Regulatory Scrutiny: The FDA and other regulatory bodies conduct inspections of manufacturing facilities and review data to ensure ongoing compliance. Failure to meet these standards can lead to warning letters, import alerts, or product recalls.
• Antitrust Concerns: In the generic space, rapid price erosion can sometimes lead to regulatory scrutiny for potential antitrust violations, though this is more common when there are very few generic players.

The main regulatory challenge for bitolterol mesylate is ensuring that generic products consistently meet the highest standards of quality and bioequivalence. Legal challenges are less likely to involve novel patent disputes and more likely to center on ensuring fair market access and compliance with existing regulations.

What is the Outlook for Bitolterol Mesylate in the Pharmaceutical Market?

The outlook for bitolterol mesylate is stable within its established generic market segment, characterized by consistent, albeit low, demand driven by cost-effectiveness and the persistent prevalence of respiratory diseases. Significant growth is unlikely.

Market Dynamics:

• Sustained Generic Demand: As long as COPD and asthma remain significant public health concerns, there will be a baseline demand for bronchodilator therapies. Bitolterol mesylate, as an affordable generic option, will continue to capture a portion of this demand, particularly in price-sensitive markets or for patients who have long been prescribed the medication.
• Competition and Price Erosion: The market will remain highly competitive due to the presence of multiple generic manufacturers. This will continue to exert downward pressure on pricing, limiting profitability for any single manufacturer.
• Limited Innovation Potential: The drug is mature, and significant investment in novel delivery systems or new indications is improbable. The focus for stakeholders will be on efficient manufacturing and distribution.
• Role in Treatment Guidelines: While newer combination therapies and advanced inhaler devices are increasingly favored in clinical guidelines for asthma and COPD, bitolterol mesylate may retain a role as a rescue inhaler or as a component of cost-conscious treatment regimens, especially where LABA/ICS or LAMA/LABA combinations are not accessible or feasible.

Investment Considerations:

• Niche Generic Play: Investment in bitolterol mesylate should be viewed as a play within the niche generic respiratory market. Success hinges on operational efficiency, supply chain strength, and market access rather than groundbreaking R&D.
• Acquisition Target for Generic Companies: Companies focused on generic portfolio expansion may consider acquiring the rights or manufacturing capabilities for bitolterol mesylate to leverage existing infrastructure and distribution networks.
• Risk Factors: Potential risks include increased regulatory scrutiny on manufacturing quality, unforeseen supply chain disruptions, or shifts in prescribing patterns that disproportionately favor newer drug classes or combination therapies.

Overall, bitolterol mesylate is expected to maintain its position as a cost-effective bronchodilator. Its future trajectory is tied to the continued need for affordable respiratory treatments and the ability of manufacturers to operate efficiently in a highly competitive generic market.

Key Takeaways

Bitolterol mesylate is a generic bronchodilator with expired primary patents, leading to intense price competition. Its market is sustained by the prevalence of COPD and asthma, but limited by advancements in inhaler technology and the dominance of newer combination therapies. Manufacturing and supply chain efficiency are critical for profitability, while regulatory compliance remains a constant requirement. The outlook is stable within its generic niche, offering limited growth but consistent demand for cost-effective respiratory treatments.

Frequently Asked Questions

1. Can new patents be filed for bitolterol mesylate?

While patents on the original compound and its initial formulations have expired, it is theoretically possible to file new patents for novel and non-obvious inventions related to bitolterol mesylate. These could include new polymorphs, novel delivery devices, combination therapies with other drugs, or new therapeutic uses discovered through research. However, the likelihood of obtaining broad protection that would significantly impact the generic market is low given the drug's age.

2. What are the primary differences between bitolterol mesylate and albuterol?

Bitolterol mesylate and albuterol are both short-acting beta-2 adrenergic agonists used to relieve bronchospasm. The key difference lies in their duration of action. Bitolterol mesylate is considered a "long-acting" beta-2 agonist, meaning its effects last longer than those of short-acting beta-2 agonists like albuterol, which are typically used for rapid, short-term relief of acute symptoms. Albuterol's onset of action is rapid, usually within minutes, while bitolterol's onset is also rapid, but its bronchodilatory effect is sustained for a longer period.

3. How does bitolterol mesylate compare to currently prescribed long-acting bronchodilators in terms of efficacy?

Clinical studies have shown bitolterol mesylate to be effective in relieving bronchospasm. However, "efficacy" in modern respiratory care involves more than just bronchodilation. Newer long-acting bronchodilators, such as those in the LABA and LAMA classes, are often studied and prescribed within the context of combination therapies (e.g., LABA/ICS, LAMA/LABA) that have demonstrated superior outcomes in managing chronic disease progression, reducing exacerbations, and improving lung function compared to monotherapy. Therefore, while bitolterol mesylate is efficacious for its indication, its comparative efficacy in achieving the broader goals of modern asthma and COPD management is less established in head-to-head trials against contemporary multi-drug regimens.

4. What regulatory hurdles must a generic manufacturer overcome to market bitolterol mesylate?

A generic manufacturer must submit an Abbreviated New Drug Application (ANDA) to the FDA (or equivalent in other regions). This application requires demonstrating:

• Bioequivalence: The generic product must be absorbed into the bloodstream at the same rate and extent as the reference listed drug.
• Quality and Manufacturing: The manufacturing process must adhere to current Good Manufacturing Practices (cGMP), ensuring consistent purity, potency, and stability of the drug product.
• Labeling: The proposed labeling must be the same as the approved labeling for the reference listed drug, with minor exceptions related to inactive ingredients.
• Patent Compliance: The manufacturer must certify that the generic product does not infringe on any existing patents or that any relevant patents are invalid, expired, or will expire before the generic product is marketed.

5. Are there any specific safety concerns associated with bitolterol mesylate compared to other beta-2 agonists?

Like all beta-2 agonists, bitolterol mesylate can cause side effects such as tremor, nervousness, headache, and palpitations. A more significant concern for the class of long-acting beta-2 agonists (LABAs), which includes bitolterol, is the potential for increased risk of asthma-related serious adverse events, including death, when used as monotherapy in patients with asthma. This has led to recommendations for LABAs to be used in combination with an inhaled corticosteroid (ICS) in asthma patients. For COPD, LABAs are a standard component of maintenance therapy. Specific comparative safety profiles between bitolterol and other LABAs are generally evaluated through large-scale clinical trials and post-market surveillance data.

---

Citations

[1] U.S. Patent No. 4,042,684. (1977). Beta-adrenergically active amino-alcohol derivatives. United States Patent and Trademark Office. [2] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Principles. Retrieved from [FDA Website] (Specific URL would be added if publicly accessible and stable) [3] European Medicines Agency. (n.d.). Guideline on the requirements for the content of the dossier of a generic medicinal product. Retrieved from [EMA Website] (Specific URL would be added if publicly accessible and stable) [4] Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). GOLD Executive Summary 2023 Report. Retrieved from [GOLD Website] (Specific URL would be added if publicly accessible and stable) [5] Global Asthma Network. (n.d.). Asthma Statistics. Retrieved from [Global Asthma Network Website] (Specific URL would be added if publicly accessible and stable)